Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The management of patients with chronic respiratory diseases have become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species, and non-tuberculous Mycobacteria (NTM). To overcome these challenges scientists are developed a noval drug formulation of antimicrobial agent and deliver drugs to the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. The important application of inhaling antibiotics is to maximize drug delivery to the target site of infection i.e. the airways and limit the potential for systemic side effects.

The global inhaled antibiotics market size was valued at US$ 1,094.6 million in 2019 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020–2027).

Figure 1: Global Inhaled Antibiotics Market Value (US$ Mn), by Region, 2020

Inhaled Antibiotics  | Coherent Market Insights

Increasing incidence of respiratory diseases is expected to drive the market growth over the forecast period

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the market growth over the forecast period.

According to the World Health Organization Report May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people were living with asthma in 2016. Similarly, according to the same source, over 80% of asthma-related deaths occur in low-and lower-middle income countries.

request-sample

Inhaled Antibiotics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,094.6 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.3% 2027 Value Projection: US$ 1,784.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Aerosol, Dry Powder Formulation, Spray.
  • By Application: Pneumonia, Asthma, Bronchitis, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.

Growth Drivers:
  • The increasing incidence of chronic respiratory disorders
  • The increasing research and development activities for development of noval products
  • The increasing adoption of inorganic growth strategies by key players operating in the market The increasing adoption of inorganic growth strategies by key players operating in the market
Restraints & Challenges:
  • Side effects allied with drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions

Moreover, according to the World Health organization 2017 report, around 251 million cases of chronic obstructive pulmonary diseases were found globally in 2016 and around 3.17 million deaths were caused by chronic obstructive pulmonary diseases in 2015. Similarly, according to the same source, more than 90% of COPD deaths occur in low and middle income countries.

Figure 2: Global Inhaled Antibiotics Market Share (%), by Product Type, (2020-2027)

Inhaled Antibiotics  | Coherent Market Insights

Increasing new product launches and approvals is expected to drive the market growth over the forecast period

Key players operating in the global market are focusing on novel product launches, in order to expand their product portfolio and increase their presence in the global market.

For instance, in October 2017, Polyphor, a Swiss specialty pharmaceutical company, launched an inhaled form of the investigational antibiotic murepavadin (POL7080). Murepavadin, a type of outer membrane protein targeting antibiotic (OMPTA), acts specifically against the bacterial strain Pseudomonas aeruginosa, which is a strain found in patients with several lung diseases, including cystic fibrosis- and non-cystic fibrosis-associated bronchiectasis.

In February 2016, Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., received approval from Health Canada for the application of its generic version of PrTeva-Tobramycin Inhalation Solution. This respiratory antibiotic is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.

Moreover, in April 2016, Raptor Pharmaceutical Corp., a biopharmaceutical company, launched its QUINSAIR (levofloxacin inhalation solution) in Germany and Denmark. It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections caused due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).

Global Inhaled Antibiotics Market - Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the World Health Organization declaring it a public health emergency. For instance, according to the World Health Organization report, as of May 15, 2020, there are 4,307,287 individuals affected with coronavirus, globally. The global impact of the coronavirus disease 2019 (COVID-19) has already begun to affect everyone and will significantly affect the inhaled antibiotics market in 2020. Increasing incidence of COVID-19 can affect the global economy by directly affecting production and demand for the products, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Inhaled Antibiotics Market Restraint

However, side effects associated with drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may hinder growth of the market.

Key Players

Major players operating in the global inhaled antibiotics market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.

Inhaled antibiotics are used to treat chronic airway infection. The earliest experience with inhaled antibiotics involved aerosolizing antibiotics designed for parenteral administration. These formulations caused significant bronchial irritation due to added preservatives and non-physiologic chemical composition. A major therapeutic advance took place when tobramycin designed for inhalation was approved by the U.S. Food and Drug Administration (FDA) for use in patients with cystic fibrosis (CF) with chronic Pseudomonas Aeruginosa infection. Increasing application of inhaled antibiotic in targeted drug delivery is expected to drive the market growth over the forecast period.

Market Dynamics

The major factors driving growth of the inhaled antibiotics market include rising incidence of chronic respiratory disorders, rapid technological advancements, and increasing research and development activities for the development of novel products. Moreover, major players operating in the global market are focusing on adoption of inorganic growth strategies such as partnership and collaboration, in order to expand its product portfolio and strengthen their research and development activities. For instance, in October 2019, Alaxia, a French biotech company, partnered with the European consortium iABC, to accelerate the development of ALX-009, an investigational inhaled antibiotic for multi-drug resistant lung infections in people with cystic fibrosis. Under the partnership, Alaxia will provide support for setting up clinical trials and recruiting patients, and will gain access to expertise on antimicrobial agents from iABC members. 

Key features of the study:

  • This report provides in-depth analysis of the global inhaled antibiotics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global inhaled antibiotics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global inhaled antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhaled antibiotics market

Detailed Segmentation:

  • Global Inhaled Antibiotics Market, By Product Type:
    • Aerosol
    • Dry Powder Formulation
    • Spray
  • Global Inhaled Antibiotics Market, By Application:
    • Pneumonia
    • Asthma
    • Bronchitis
    • Others
  • Global Inhaled Antibiotics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Inhaled Antibiotics Market, By Region:
    • North America
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • S.
        • Canada
    • Latin America
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Aerosol
        • Dry Powder Formulation
        • Spray
      • By Application:
        • Pneumonia
        • Asthma
        • Bronchitis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Gilead Sciences *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Aradigm
    • Lupin Ltd.
    • Polyphor
    • Insmed Incorporated
    • Pharmaero
    • Savara Pharmaceuticals
    • Joincare Pharmaceutical Group
    • Pharmaxis Ltd

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Merger and Acquisition Scenario
    • PEST Analysis
  4. Global Inhaled Antibiotics Market – Impact of Coronavirus (Covid-19) Pandemic
    • Impact assessment
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Government measures to combat COVID-19
  5. Global Inhaled Antibiotics Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Aerosol
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Dry Powder Formulation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Spray
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Inhaled Antibiotics Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pneumonia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Asthma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bronchitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Inhaled Antibiotics Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Inhaled Antibiotics Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Gilead Sciences *
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aradigm
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Polyphor
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Insmed Incorporated
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharmaero
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Savara Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Joincare Pharmaceutical Group
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharmaxis Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 30 figures on "Inhaled Antibiotics Market” - Global forecast to 2027.

Frequently Asked Questions

The global inhaled antibiotics market size was valued at US$ 1,160.69 million in 2020 and is expected to exhibit a CAGR of 6.3% between 2020 and 2027.
Aerosol segment held the major market share in 2019, owing to novel products developed by key players operating in the market.
Major factors driving growth of the global inhaled antibiotics market are increasing incidence of chronic respiratory disorders such as asthma and COPD, increasing product launches and approvals, and adoption of expansion strategies by key market players.
Major factors hampering growth of the inhaled antibiotics market are side effects allied with the drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions.
North America inhaled antibiotics market is expected to generate the largest revenue in 2019.
Some of the key players operating in the market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner